Literature DB >> 32284427

Parental Considerations Regarding Cure and Late Effects for Children With Cancer.

Katie A Greenzang1,2,3, Hasan Al-Sayegh4,3, Clement Ma, Mehdi Najafzadeh5, Eve Wittenberg6, Jennifer W Mack4,2,3.   

Abstract

BACKGROUND: More than 80% of children with cancer become long-term survivors, yet most survivors experience late effects of treatment. Little is known about how parents and physicians consider late-effects risks against a potential survival benefit when making treatment decisions.
METHODS: We used a discrete choice experiment to assess the importance of late effects on treatment decision-making and acceptable trade-offs between late-effects risks and survival benefit. We surveyed 95 parents of children with cancer and 41 physicians at Dana-Farber/Boston Children's Cancer and Blood Disorders Center to assess preferences for 5 late effects of treatment: neurocognitive impairment, infertility, cardiac toxicity, second malignancies, and impaired growth and development.
RESULTS: Each late effect had a statistically significant association with treatment choice, as did survival benefit (P < .001). Avoidance of severe cognitive impairment was the most important treatment consideration to parents and physicians. Parents also valued cure and decreased risk of second malignancies; physician decision-making was driven by avoidance of second malignancies and infertility. Both parents and physicians accepted a high risk of infertility (parents, a 137% increased risk; physicians, an 80% increased risk) in exchange for a 10% greater chance of cure.
CONCLUSIONS: Avoidance of severe neurocognitive impairment was the predominant driver of parent and physician treatment preferences, even over an increased chance of cure. This highlights the importance of exploring parental late-effects priorities when discussing treatment options.
Copyright © 2020 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2020        PMID: 32284427      PMCID: PMC7193979          DOI: 10.1542/peds.2019-3552

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  40 in total

Review 1.  Challenges after curative treatment for childhood cancer and long-term follow up of survivors.

Authors:  Kevin C Oeffinger; Paul C Nathan; Leontien C M Kremer
Journal:  Hematol Oncol Clin North Am       Date:  2010-02       Impact factor: 3.722

Review 2.  Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.

Authors:  Daniel M Green; Larry E Kun; Katherine K Matthay; Anna T Meadows; William H Meyer; Paul A Meyers; Sheri L Spunt; Leslie L Robison; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2013-02-15       Impact factor: 3.167

3.  Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force.

Authors:  A Brett Hauber; Juan Marcos González; Catharina G M Groothuis-Oudshoorn; Thomas Prior; Deborah A Marshall; Charles Cunningham; Maarten J IJzerman; John F P Bridges
Journal:  Value Health       Date:  2016-05-12       Impact factor: 5.725

4.  Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents.

Authors:  S Saigal; B L Stoskopf; D Feeny; W Furlong; E Burrows; P L Rosenbaum; L Hoult
Journal:  JAMA       Date:  1999-06-02       Impact factor: 56.272

5.  Communication About Prognosis With Adolescent and Young Adult Patients With Cancer: Information Needs, Prognostic Awareness, and Outcomes of Disclosure.

Authors:  Jennifer W Mack; Karen M Fasciano; Susan D Block
Journal:  J Clin Oncol       Date:  2018-04-23       Impact factor: 44.544

6.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force.

Authors:  F Reed Johnson; Emily Lancsar; Deborah Marshall; Vikram Kilambi; Axel Mühlbacher; Dean A Regier; Brian W Bresnahan; Barbara Kanninen; John F P Bridges
Journal:  Value Health       Date:  2013 Jan-Feb       Impact factor: 5.725

7.  Attitudes toward neonatal intensive care treatment of preterm infants with a high risk of developing long-term disabilities.

Authors:  Hugh Simon Lam; Samuel Po Shing Wong; Flora Yuen Big Liu; Hiu Lei Wong; Tai Fai Fok; Pak Cheung Ng
Journal:  Pediatrics       Date:  2009-06       Impact factor: 7.124

8.  Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger
Journal:  JAMA       Date:  2003-09-24       Impact factor: 157.335

9.  Parent perspectives on information about late effects of childhood cancer treatment and their role in initial treatment decision making.

Authors:  Katie A Greenzang; Angela Dauti; Jennifer W Mack
Journal:  Pediatr Blood Cancer       Date:  2018-01-30       Impact factor: 3.838

10.  The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE).

Authors:  Nickhill Bhakta; Qi Liu; Kirsten K Ness; Malek Baassiri; Hesham Eissa; Frederick Yeo; Wassim Chemaitilly; Matthew J Ehrhardt; Johnnie Bass; Michael W Bishop; Kyla Shelton; Lu Lu; Sujuan Huang; Zhenghong Li; Eric Caron; Jennifer Lanctot; Carrie Howell; Timothy Folse; Vijaya Joshi; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Kevin R Krull; Tara M Brinkman; Raja B Khan; Deo K Srivastava; Melissa M Hudson; Yutaka Yasui; Leslie L Robison
Journal:  Lancet       Date:  2017-09-08       Impact factor: 79.321

View more
  2 in total

1.  Thinking ahead: Parents' worries about late effects of childhood cancer treatment.

Authors:  Katie A Greenzang; Colleen A Kelly; Hasan Al-Sayegh; Clement Ma; Jennifer W Mack
Journal:  Pediatr Blood Cancer       Date:  2021-09-14       Impact factor: 3.167

2.  Parental decision making regarding consent to randomization on Children's Oncology Group AALL0932.

Authors:  Kellee Parker; Erika Cottrell; Linda Stork; Susan Lindemulder
Journal:  Pediatr Blood Cancer       Date:  2021-01-26       Impact factor: 3.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.